Literature DB >> 10648939

Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7.

Q Zhu1, C Zeng, A Huhalov, J Yao, T G Turi, D Danley, T Hynes, Y Cong, D DiMattia, S Kennedy, G Daumy, E Schaeffer, W A Marasco, J S Huston.   

Abstract

8 h) and high steady-state levels of protein accumulation, while the H2 intrabodies had a half-life of 2 h and less protein at steady state. These results suggest that the choice of sFv as an intrabody depends critically on the intracellular sFv protein having an extended half-life and elevated steady-state level. Thus, extended half-life must be considered together with sFv antibody specificity and affinity when choosing an optimal sFv intrabody for functional studies of cellular proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10648939     DOI: 10.1016/s0022-1759(99)00158-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.

Authors:  Kelly L Sudol; Michael A Mastrangelo; Wade C Narrow; Maria E Frazer; Yona R Levites; Todd E Golde; Howard J Federoff; William J Bowers
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

3.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.

Authors:  David W Colby; Yijia Chu; John P Cassady; Martin Duennwald; Helen Zazulak; Jack M Webster; Anne Messer; Susan Lindquist; Vernon Martin Ingram; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

4.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Authors:  Erik Kvam; Michael R Sierks; Charles B Shoemaker; Anne Messer
Journal:  Protein Eng Des Sel       Date:  2010-04-08       Impact factor: 1.650

5.  Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.

Authors:  Liang Li; Christopher S Gondi; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 6.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

7.  Efficient isolation of soluble intracellular single-chain antibodies using the twin-arginine translocation machinery.

Authors:  Adam C Fisher; Matthew P DeLisa
Journal:  J Mol Biol       Date:  2008-11-01       Impact factor: 5.469

8.  Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.

Authors:  Shubhada N Joshi; David C Butler; Anne Messer
Journal:  MAbs       Date:  2012-08-28       Impact factor: 5.857

9.  The Pyk2 FERM domain as a target to inhibit glioma migration.

Authors:  Joseph C Loftus; Zhongbo Yang; Nhan L Tran; Jean Kloss; Carole Viso; Michael E Berens; Christopher A Lipinski
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

10.  Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis.

Authors:  Maria Gabriella Donà; Colomba Giorgi; Luisa Accardi
Journal:  BMC Cancer       Date:  2007-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.